Pharvaris (NASDAQ:PHVS) Upgraded to Hold at Wall Street Zen

Pharvaris (NASDAQ:PHVS) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

A number of other research firms have also weighed in on PHVS. Oppenheimer increased their price objective on Pharvaris from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Thursday, December 4th. Bank of America increased their price target on shares of Pharvaris from $27.00 to $30.00 and gave the company a “neutral” rating in a research report on Thursday, December 4th. Leerink Partners set a $38.00 price target on shares of Pharvaris in a report on Wednesday, December 3rd. Morgan Stanley upped their price objective on shares of Pharvaris from $37.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday, December 4th. Finally, Citigroup reissued a “market outperform” rating on shares of Pharvaris in a research note on Wednesday, November 19th. Nine analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Pharvaris presently has an average rating of “Moderate Buy” and a consensus price target of $40.56.

Pharvaris Stock Up 5.1%

Shares of NASDAQ:PHVS opened at $26.42 on Friday. The stock’s 50-day moving average price is $26.01 and its 200-day moving average price is $24.00. Pharvaris has a 12-month low of $11.51 and a 12-month high of $29.80.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Wednesday, November 12th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.08. On average, equities research analysts predict that Pharvaris will post -2.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pharvaris

Large investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. bought a new position in Pharvaris in the fourth quarter worth about $35,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new position in shares of Pharvaris during the 2nd quarter worth approximately $57,000. JPMorgan Chase & Co. grew its holdings in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in shares of Pharvaris in the 3rd quarter worth approximately $75,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Pharvaris in the 4th quarter valued at approximately $86,000.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.